FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1994418770> ?p ?o ?g. }

• W1994418770 endingPage "8393" @default.
• W1994418770 startingPage "8386" @default.
• W1994418770 abstract "Proteasome inhibitor PS-341 is one of the most promising novel agents against multiple myeloma (MM). We have previously shown that PS-341 inhibits IL-6 triggered phosphorylation of extracellular signal-regulated kinases (ERK) 1/2 (also known as p42/44 mitogen-activated protein kinases) in MM cells. In this study, we further examined whether clinically achievable concentrations of PS-341 could inhibit IL-6 triggered signaling cascades in MM. We found that PS-341 inhibited not only ERK, but also signal transducers and activators of transcription (STAT) 3 as well as Akt phosphorylation. Since gp130 (CD130) dimerizes and is phosphorylated after IL-6 binding to gp80 (IL-6 receptor), we hypothesized that gp130 could be involved in PS-341-induced blockade of signaling cascades mediating MM cell growth, survival, and drug resistance in the bone marrow (BM) microenvironment. In this study, we first demonstrate that PS-341 induces downregulation of gp130 in a time- and dose-dependent manner in vitro, prior to MM cell death. Conversely, downregulation of gp130 is completely abrogated by the pan-caspase inhibitor Z-VAD-FMK, suggesting that downregulation of gp130 is mediated via caspase activation. Z-VAD-FMK also abrogates the inhibitory effect of PS-341 on IL-6-triggered signaling cascades. Importantly, we demonstrate that phosphorylation of ERK, STAT3, and Akt in MM.1S cells induced by either exogenous IL-6 or by binding of MM cells to BM stromal cells is abrogated by PS-341. These studies, therefore, define another novel mechanism whereby PS-341 can overcome the growth and survival advantage in MM cells conferred by the BM milieu. Importantly, this effect on cytokine-induced gp130 signaling cascades may account, at least in part, for the remarkable preclinical sensitivity and clinical responses achieved in MM with PS-341 treatment." @default.
• W1994418770 created "2016-06-24" @default.
• W1994418770 creator A5006765393 @default.
• W1994418770 creator A5007023688 @default.
• W1994418770 creator A5008159204 @default.
• W1994418770 creator A5010021766 @default.
• W1994418770 creator A5010152323 @default.
• W1994418770 creator A5012712111 @default.
• W1994418770 creator A5032464400 @default.
• W1994418770 creator A5043526996 @default.
• W1994418770 creator A5045740077 @default.
• W1994418770 creator A5091207345 @default.
• W1994418770 date "2003-11-20" @default.
• W1994418770 modified "2023-10-16" @default.
• W1994418770 title "Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma" @default.
• W1994418770 cites W139500099 @default.
• W1994418770 cites W1520422891 @default.
• W1994418770 cites W1568956696 @default.
• W1994418770 cites W1759028523 @default.
• W1994418770 cites W1963678818 @default.
• W1994418770 cites W1977348505 @default.
• W1994418770 cites W1980471295 @default.
• W1994418770 cites W1985208420 @default.
• W1994418770 cites W1996548067 @default.
• W1994418770 cites W2003757684 @default.
• W1994418770 cites W2007000374 @default.
• W1994418770 cites W2007119824 @default.
• W1994418770 cites W2007998678 @default.
• W1994418770 cites W2011485061 @default.
• W1994418770 cites W2015975538 @default.
• W1994418770 cites W2024969918 @default.
• W1994418770 cites W2028071443 @default.
• W1994418770 cites W2045560618 @default.
• W1994418770 cites W2051256348 @default.
• W1994418770 cites W2058347762 @default.
• W1994418770 cites W2059873406 @default.
• W1994418770 cites W2065522904 @default.
• W1994418770 cites W2070739194 @default.
• W1994418770 cites W2072493113 @default.
• W1994418770 cites W2075262248 @default.
• W1994418770 cites W2079067660 @default.
• W1994418770 cites W2090786978 @default.
• W1994418770 cites W2101036669 @default.
• W1994418770 cites W2118310862 @default.
• W1994418770 cites W2146502962 @default.
• W1994418770 cites W2154374454 @default.
• W1994418770 cites W2165980203 @default.
• W1994418770 cites W4244689496 @default.
• W1994418770 cites W4245229780 @default.
• W1994418770 cites W4247411497 @default.
• W1994418770 cites W4247912414 @default.
• W1994418770 cites W91158829 @default.
• W1994418770 doi "https://doi.org/10.1038/sj.onc.1207170" @default.
• W1994418770 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14627979" @default.
• W1994418770 hasPublicationYear "2003" @default.
• W1994418770 type Work @default.
• W1994418770 sameAs 1994418770 @default.
• W1994418770 citedByCount "157" @default.
• W1994418770 countsByYear W19944187702012 @default.
• W1994418770 countsByYear W19944187702013 @default.
• W1994418770 countsByYear W19944187702014 @default.
• W1994418770 countsByYear W19944187702015 @default.
• W1994418770 countsByYear W19944187702016 @default.
• W1994418770 countsByYear W19944187702017 @default.
• W1994418770 countsByYear W19944187702018 @default.
• W1994418770 countsByYear W19944187702020 @default.
• W1994418770 countsByYear W19944187702021 @default.
• W1994418770 countsByYear W19944187702022 @default.
• W1994418770 countsByYear W19944187702023 @default.
• W1994418770 crossrefType "journal-article" @default.
• W1994418770 hasAuthorship W1994418770A5006765393 @default.
• W1994418770 hasAuthorship W1994418770A5007023688 @default.
• W1994418770 hasAuthorship W1994418770A5008159204 @default.
• W1994418770 hasAuthorship W1994418770A5010021766 @default.
• W1994418770 hasAuthorship W1994418770A5010152323 @default.
• W1994418770 hasAuthorship W1994418770A5012712111 @default.
• W1994418770 hasAuthorship W1994418770A5032464400 @default.
• W1994418770 hasAuthorship W1994418770A5043526996 @default.
• W1994418770 hasAuthorship W1994418770A5045740077 @default.
• W1994418770 hasAuthorship W1994418770A5091207345 @default.
• W1994418770 hasBestOaLocation W19944187701 @default.
• W1994418770 hasConcept C104317684 @default.
• W1994418770 hasConcept C11960822 @default.
• W1994418770 hasConcept C126037660 @default.
• W1994418770 hasConcept C127561419 @default.
• W1994418770 hasConcept C153911025 @default.
• W1994418770 hasConcept C16930146 @default.
• W1994418770 hasConcept C184235292 @default.
• W1994418770 hasConcept C27740335 @default.
• W1994418770 hasConcept C2778367456 @default.
• W1994418770 hasConcept C2778506107 @default.
• W1994418770 hasConcept C2778923194 @default.
• W1994418770 hasConcept C502942594 @default.
• W1994418770 hasConcept C55493867 @default.
• W1994418770 hasConcept C57074206 @default.
• W1994418770 hasConcept C62478195 @default.
• W1994418770 hasConcept C75217442 @default.
• W1994418770 hasConcept C86803240 @default.

• next